merck p53 peptide patent peptide - sk-peptides EP3256484A1 Merck's Pioneering Work in p53 Peptide Patents and Therapeutics

skin-health-peptides-pittsburgh Merck, a global leader in science and technology, has been at the forefront of developing innovative therapeutic strategies, particularly in the realm of oncology. A significant area of focus for Merck and its subsidiaries, such as MERCK PATENT GMBH, involves the exploration and patenting of p53 peptide-based technologiesPatents In BindingDB. These advancements are crucial for developing novel treatments that target the p53 tumor suppressor gene, a critical player in cancer development and progression. The merck p53 peptide patent landscape reveals a deep commitment to unlocking the therapeutic potential of peptides that interact with the p53 pathway.United States Patent - Googleapis.com

The p53 protein is often referred to as the "guardian of the genome" due to its role in preventing mutations and maintaining genomic stability.CLSP-1025 is designed to target the p53 R175H peptidein the context of HLA-A*02:01. Enrolled patients must be HLA-A*02:01 positive and have an advanced ... However, in a vast majority of human cancers, p53 is mutated or inactivated, leading to uncontrolled cell growth and resistance to therapy. Consequently, researchers are actively pursuing ways to restore p53 function or leverage its mechanisms for therapeutic benefit. This has led to the development of various peptides designed to modulate p53 activity, and Merck's patents highlight their contributions to this burgeoning field.The RB and p53 pathways in cancer - ScienceDirect.com

One key area of research, as evidenced by US9527896B2, focuses on "Stabilized p53 peptides and uses thereof." These stabilized alpha-helix of p53 (SAH-p53) peptides are engineered to exhibit high affinity for HDM2, a protein that normally inhibits p53. By stabilizing the alpha-helical structure of the p53 peptide, these compounds can effectively disrupt the p53-HDM2 interaction, thereby reactivating p53's tumor-suppressing functions.The invention providespeptides that can reactivate p53 mutantsefficiently and specifically, as well as methods that allow the identification, ... This approach represents a significant step beyond unmodified p53 peptides, offering enhanced stability and therapeutic efficacy.

Furthermore, the development of peptides that can reactivate p53 mutants is another critical avenue being explored.作者：EHC Hsiue·2021·被引用次数：370—Hsiue et al. discovered a way to target a cancer-associated mutant form of thep53protein using the body's own immune system. Many cancers harbor missense mutations in the p53 gene, rendering the protein inactive or prone to degradationPhase 2a study of a novel stapled peptide ALRN-6924 .... Patents like US8343760B2 describe " p53 activator peptides," involving novel polypeptides that activate p53. These innovations aim to restore the function of mutated p53 proteins or to introduce peptides that can compensate for their loss. The pursuit of such peptides is vital for treating a broad spectrum of cancers driven by p53 dysfunction.

The patent landscape surrounding p53 is rich with diverse strategies. For instance, research into p53 biomarkers, as indicated by EP3159696A1, aims to identify p53 biomarker profiles that predict patient response to therapies. This is crucial for personalized medicine, ensuring that the right treatments are administered to the right patients.Discovery of Compounds that reactivate p53 mutants in ... Additionally, the development of specific inhibitors, such as CLSP-1025, which is designed to target the p53 R175H peptide in the context of certain genetic profiles, exemplifies the precision required in modern cancer therapeutics.

Merck's involvement extends to collaborations and the development of cutting-edge peptide technologies.作者：J Michels·2024·被引用次数：4—We demonstrate that APR-246 and its active moiety, methylene quinuclidinone (MQ) can enhance the immunogenicity of tumor cells directly. The mention of Merck in relation to peptide advancements, including have a patent issued for specific peptides, underscores their active participation. For example, the stapled peptide technology, exemplified by ALRN-6924, which is a cell-penetrating stapled alpha-helical peptide, represents a significant leap in drug design. These stapled peptides, including ALRN-6924, the first-in-class clinical stage stapled peptide, are structurally stabilized in an alpha-helical configuration to mimic natural protein interactions, such as the disruption of the p53-MDM2 axis. Another related patent, EP3256484A1, further illustrates Merck's engagement in this area.

The scientific community's interest in p53 extends to understanding its molecular basis, as seen in studies on the inhibition of p53 by Mdm2 and Mdmx. The p53 peptide forming an amphipathic helix highly complementary to the hydrophobic pocket at the Mdm2 surface is a key insight driving the design of p53 modulators. The exploration of p53 mutations, such as the p53 Y220C mutation, and the development of specific reactivators like Rezatapopt (PC14586) further highlight the intense research efforts in this field.

Beyond direct p53 activation, Merck has also been involved in broader cancer therapeutic strategies, including the development of antibodies and collaborations for small molecule discovery.2025年8月8日—The Stapled Peptide PM2 Stabilizes p53 ... Merck on macrocyclic. peptides. DL and CB have a patentEP3256484A1pending. The authors declare. For instance, the anti-p53 (wild type) Antibody, clone PAb1620, while not directly a Merck patent, represents the type of research tools and reagents that are essential for studying p53 and developing related therapies. Similarly, the collaboration between Astex Pharmaceuticals and Merck (MSD) to discover small molecule candidates for cancer treatment signifies a commitment to diverse therapeutic modalitiesCLSP-1025 is designed to target the p53 R175H peptidein the context of HLA-A*02:01. Enrolled patients must be HLA-A*02:01 positive and have an advanced ....

In summary, the merck p53 peptide patent and related research efforts underscore a sophisticated and multi-faceted approach to tackling cancer作者：G Durairaj·2022·被引用次数：28—The tumor suppressorp53is the most frequently mutated protein in human cancer. The majority of these mutations are missense mutations in the DNA binding .... From stabilized p53 peptides and peptides that can reactivate p53 mutants to advancements in peptide engineering and biomarker identification, Merck is actively shaping the future of p53-targeted therapies. The continuous innovation in peptide science, coupled with strategic patenting, positions Merck as a key player in the fight against cancer by harnessing the power of the p53 pathway. The company's dedication to research, evidenced by numerous patents and publications, reflects a deep understanding of the complexities of p53 biology and its therapeutic implications.